Who
Marlio Charles Mosseri
10% owner
Company insider
Files Form 4 as: 10% owner, Nuvectis Pharma.
In numbers
- Trades disclosed
- 47
- Buys
- 36
- Sells
- 0
- Bought
- $8.8M
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 15 Jun 2023
- Last trade
- 30 Jun 2026
- Last filed
- 1 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 1 Jul 2026 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $916K50,000 at $18.32 | filing |
| 30 Jun 2026filed 1 Jul 2026 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $916K50,000 at $18.32 | filing |
| 27 Oct 2025filed 29 Oct 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $457K72,836 at $6.28 | filing |
| 24 Oct 2025filed 29 Oct 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $215K35,034 at $6.15 | filing |
| 23 Oct 2025filed 29 Oct 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $284K46,900 at $6.06 | filing |
| 20 Jun 2025filed 24 Jun 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $45K5,603 at $7.99 | filing |
| 18 Jun 2025filed 20 Jun 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $226K28,043 at $8.05 | filing |
| 17 Jun 2025filed 20 Jun 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $44K5,399 at $8.11 | filing |
| 12 May 2025filed 13 May 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $172K21,167 at $8.11 | filing |
| 9 May 2025filed 12 May 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $88K9,850 at $8.95 | filing |
| 9 May 2025filed 12 May 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $87K9,817 at $8.90 | filing |
| 9 May 2025filed 12 May 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $48K5,395 at $8.98 | filing |
| 8 May 2025filed 12 May 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $899100 at $8.99 | filing |
| 8 May 2025filed 12 May 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $871100 at $8.71 | filing |
| 8 May 2025filed 12 May 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $22K2,400 at $8.97 | filing |
| 8 May 2025filed 9 May 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $43350 at $8.65 | filing |
| 8 May 2025filed 9 May 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $865100 at $8.65 | filing |
| 8 May 2025filed 9 May 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $865100 at $8.65 | filing |
| 8 May 2025filed 9 May 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $21K2,400 at $8.65 | filing |
| 7 May 2025filed 9 May 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $23K2,703 at $8.40 | filing |
News
Nuvectis Pharma (NASDAQ:NVCT) Stock Falls 6.8% – Here's WhyNVCT · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name Marlio Charles Mosseri; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.